Could custom doses of prostate cancer radiation be safer and stronger?
NCT ID NCT06943495
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tests whether giving a personalized dose of the drug 177Lu-PSMA-617 (Pluvicto) based on kidney function is safer and allows higher doses than the standard fixed dose. Sixty men with metastatic castration-resistant prostate cancer will receive either personalized or fixed doses over six cycles. The goal is to see if personalization can safely increase the amount of radiation delivered.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- 177Lu-PSMA-617 (Lutetium Lu 177 vipivotide tetraxetan, also known as Pluvicto)
- What this could lead to
- If successful, this could show that tailoring radiation doses to each patient improves safety and effectiveness for treating advanced prostate cancer.
- What could go wrong
- This is a small early-phase pilot study, so results may not apply broadly. There are risks of serious side effects like low blood counts or kidney damage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATE RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU de Québec-Université Laval
RECRUITINGQuébec, Quebec, G1R2J6, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug help when standard therapy falls short for prostate cancer?
- New hope for Hard-to-Treat prostate cancer: drug combo trial launches
- New drug combo takes on tough cancers in early trial
- Real-World data reveals early use of prostate cancer drug in thousands of patients
- Immune cells armed with cancer-seeking antibodies tested in advanced cancers
- Supercharged immune cells take on Hard-to-Treat prostate cancer